2016 American Transplant Congress
Predictors of eGFR Slope at One Year in Kidney Transplants – A Big Data Approach.
Background: Estimated glomerular filtration rate (eGFR), a predictor of graft loss (GL) in kidney transplantation could inform intervention. National data yield eGFRs at fixed time…2016 American Transplant Congress
Natural History of Response to Wounding in Human Kidney Transplants.
In both primary kidney diseases and kidney transplants, the extent of fibrosis is a key indicator of stage, progression, and prognosis. Much debate focuses, however,…2016 American Transplant Congress
Impact of Machine Perfusion on Long-Term Kidney Transplant Outcomes.
1MUHC, Montreal, Canada; 2JHU, Baltimore.
Machine perfusion (MP) has been shown to decrease DGF rates in kidney transplant (KT) recipients when compared with static cold storage (CS). However, there is…2016 American Transplant Congress
Optimal Donor/Recipient Pairing for High KDPI Grafts Can Yield Similar Survival to Medium KDPI Grafts.
Medical College of Wisconsin, Milwaukee.
KDPI is a predictor of deceased-donor (DD) graft survival, calculated using donor factors. It does not consider recipient or other post-procurement factors. This retrospective analysis…2016 American Transplant Congress
Polyclonal Treg Adoptive Therapy for Control of Subclinical Kidney Transplant Inflammation (TASK Pilot Trial).
Purpose: Early renal graft inflammation is associated with progressive fibrosis & late dysfunction. Treg therapy can reverse established inflammation in animal models. We conducted a…2016 American Transplant Congress
A Molecular Biopsy Test for Probability of Non-Adherence.
Afferent arteriolar hyalinosis (ah-score) in renal transplant biopsies increases with time of biopsy-post-transplant (TxBx), reflecting calcineurin inhibitor drug effects, donor aging, and progressive glomerular diseases.…2016 American Transplant Congress
Blockade of HLA Antibody-Triggered Classical Complement Activation by High-Affinity Humanized Monoclonal Anti-C1s Antibody TNT009 – Results of a First-in-Human Phase 1 Trial.
Study purpose: Classical complement may play a key role in ABMR. A promising therapeutic approach could be complement inhibition at the level of key component…2016 American Transplant Congress
Investigating Posttransplant Allo-Donor Specific CD57+ Cells in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.
Department of Surgery, Duke University, Durham, NC.
Recent studies have showed correlation between CD4+CD57+PD1- cells and costimulation blockade resistant rejection (CoBRR) in patients treated with belatacept without depletional induction. We have recently…2016 American Transplant Congress
Anti-IL6R Therapy (Tocilizumab) Improves Long-Term Patient & Graft Survival in Patients with Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy.
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction:Extending the functionality of renal allografts is an essential goal of transplant medicine. HS patients (pts) are at increased risk for chronic ABMR (CABMR) due…2016 American Transplant Congress
Establishing the Relationship Between Receptor Occupancy, Serum Exposure and Pathway Inhibition by the Blocking, Non-Depleting Anti-CD40 Antibody CFZ533 to Inform Dose Selection in Clinical Transplantation.
Novartis Institutes for Biomedical Research, Basel, Switzerland.
Background. CD40-CD154 pathway blockade significantly prolongs renal allograft survival in non-human primates (NHPs), and trials of the novel blocking, non-depleting anti-CD40 monoclonal antibody (mAb) CFZ533…
American Transplant Congress abstracts